Jump to main content
Jump to site search

Issue 9, 2011
Previous Article Next Article

Optimized glucuronidation of dual pharmacology β-2 agonists/M3 antagonists for the treatment of COPD

Author affiliations

Abstract

‘Inhalation by design’ concepts were developed to create novel dual pharmacology β-2 agonists-M3 antagonists, for the treatment of chronic obstructive pulmonary disorder. A key feature of this work is the combination of balanced potency and pharmacological duration with optimised glucuronidation through the incorporation of metabolically vulnerable phenols.

Graphical abstract: Optimized glucuronidation of dual pharmacology β-2 agonists/M3 antagonists for the treatment of COPD

Back to tab navigation

Supplementary files

Publication details

The article was received on 27 May 2011, accepted on 20 Jun 2011 and first published on 11 Jul 2011


Article type: Concise Article
DOI: 10.1039/C1MD00140J
Med. Chem. Commun., 2011,2, 870-876

  •   Request permissions

    Optimized glucuronidation of dual pharmacology β-2 agonists/M3 antagonists for the treatment of COPD

    L. Hilton, R. Osborne, A. S. Kenyon, H. Baldock, M. E. Bunnage, J. Burrows, N. Clarke, M. Coghlan, D. Entwistle, D. Fairman, N. Feeder, K. James, R. M. Jones, N. Laouar, G. Lunn, S. Marshall, S. D. Newman, S. Patel, M. D. Selby, F. Spence, E. F. Stuart, S. Summerhill, M. A. Trevethick, K. N. Wright, M. Yeadon, D. A. Price and L. H. Jones, Med. Chem. Commun., 2011, 2, 870
    DOI: 10.1039/C1MD00140J

Search articles by author

Spotlight

Advertisements